ASCO 2020 | ASPEN: zanubrutinib versus ibrutinib in patients with WM
Constantine Tam
• 13 May 2020
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, of The Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results of the ASPEN study (NCT03053440), the first completed clinical trial comparing the efficacy of two BTK inhibitors in any disease. The results of the study suggest that zanubrutinib is associated with a reduced incidence of adverse events including cardiotoxicity. During prolonged follow up, partial remission in Waldenström macroglobulinemia is shown to be significantly greater than patients treated with ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
